A microbial supply chain for production of the anti-cancer drug vinblastine.
Zhang J, Hansen LG, Gudich O, Viehrig K, Lassen LMM, Schrübbers L, Adhikari KB, Rubaszka P, Carrasquer-Alvarez E, Chen L, D'Ambrosio V, Lehka B, Haidar AK, Nallapareddy S, Giannakou K, Laloux M, Arsovska D, Jørgensen MAK, Chan LJG, Kristensen M, Christensen HB, Sudarsan S, Stander EA, Baidoo E, Petzold CJ, Wulff T, O'Connor SE, Courdavault V, Jensen MK, Keasling JD. · 2022
Read A microbial supply chain for production of the anti-cancer drug vinblastine. by Zhang J, Hansen LG, Gudich O, Viehrig K, Lassen LMM, Schrübbers L, Adhikari KB, Rubaszka P, Carrasquer-Alvarez E, Chen L, D'Ambrosio V, Lehka B, Haidar AK, Nallapareddy S, Giannakou K, Laloux M, Arsovska D, Jørgensen MAK, Chan LJG, Kristensen M, Christensen HB, Sudarsan S, Stander EA, Baidoo E, Petzold CJ, Wulff T, O'Connor SE, Courdavault V, Jensen MK, Keasling JD. (2022) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc9452304.txt.
Introduction
Zhang and co-authors build a microbial supply chain for the anti-cancer drug vinblastine. The drug comes from a plant alkaloid family that is hard to make by chemistry. Supply now rests on low-yield extraction from the plant Catharanthus roseus. Two plant precursors are pulled out and coupled in a lab step.
The team rebuilt the whole path inside engineered yeast. The route runs 30 enzymatic steps past the yeast's own starting compounds. In total, 56 genetic edits were made to the strain. Those edits added 34 plant genes and tuned ten yeast genes. The yeast makes both precursors from scratch. A chemical step then joins them into vinblastine. The authors say yeast could now supply more than 3,000 kin compounds.
Catalog record
| CREATOR | Zhang J, Hansen LG, Gudich O, Viehrig K, Lassen LMM, Schrübbers L, Adhikari KB, Rubaszka P, Carrasquer-Alvarez E, Chen L, D'Ambrosio V, Lehka B, Haidar AK, Nallapareddy S, Giannakou K, Laloux M, Arsovska D, Jørgensen MAK, Chan LJG, Kristensen M, Christensen HB, Sudarsan S, Stander EA, Baidoo E, Petzold CJ, Wulff T, O'Connor SE, Courdavault V, Jensen MK, Keasling JD. |
|---|---|
| YEAR | 2022 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 70 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
A microbial supply chain for production of the anti-cancer drug vinblastine By Jie Zhang, Lea G Hansen, Olga Gudich, Konrad Viehrig, Lærke M M Lassen, Lars Schrübbers, Khem B Adhikari, Paulina Rubaszka, Elena Carrasquer-Alvarez, Ling Chen, Vasil D’Ambrosio, Beata Lehka Published in: Nature DOI: 10.1038/s41586-022-05157-3 ABSTRACT Abstract Monoterpene indole alkaloids (MIAs) are a diverse family of complex plant secondary metabolites with many medicinal properties, including the essential anti-cancer therapeutics vinblastine and vincristine1. As MIAs are difficult to chemically synthesize, the world’s supply chain for vinblastine relies on low-yielding extraction and purification of the precursors vindoline and catharanthine from the plant Catharanthus roseus, which is then followed by simple in vitro chemical coupling and reduction to form vinblastine at an industrial scale2,3. Here, we demonstrate the de novo microbial biosynthesis of vindoline and catharanthine using a highly engineered yeast, and in vitro chemical coupling to vinblastine. The study showcases a very long biosynthetic pathway refactored into a microbial cell factory, including 30 enzymatic steps beyond the yeast native metabolites geranyl pyrophosphate and tryptophan to catharanthine and vindoline. In total, 56 genetic edits were performed, including expression of 34 heterologous genes from plants, as well as deletions, knock-downs and overexpression of ten yeast genes to improve precursor supplies towards de novo production of catharanthine and vindoline, from which semisynthesis to vinblastine occurs. As the vinblastine pathway is one of the longest MIA biosynthetic pathways, this study positions yeast as a scalable platform to produce more than 3,000 natural MIAs and a virtually infinite number of new-to-nature analogues. Subject terms: Metabolic engineering, Cell biology MAIN Plants produce some of the most potent human therapeutics and have been used for millennia to treat illnesses. The monoterpene indole alkaloids (MIAs) are plant secondary metabolites mostly found in Gentianales plants, bolstering a notable structural diversity and pharmaceutically valuable biological activities, with more than 3,000 MIAs derived from their common precursor strictosidine4,5. The MIA chemotherapeutic drugs irinotecan, vinblastine and vincristine are included in the World Health Organization list of essential medicines and exemplify some of the few established MIA therapeutics on the market, with annual market sizes of more than €1 billion (ref. 6). Despite the vast repertoire of MIAs with documented bioactivities, obtaining requisite amounts of MIAs needed for further development and clinical applications is often challenging because of the low yields observed in extracts from natural plant resources, as exemplified by the chemotherapeutic drugs vinblastine and vincristine requiring 500 and 2,000 kg of Catharanthus roseus dried leaves, respectively, to obtain 1 g of products3,7,8. Likewise, owing to the numerous stereo centres found in MIAs, multi-step synthetic chemistry holds little promise for bulk production of complex MIA therapeutics2,9, and thus the current vinblastine supply chains rely on extraction from C. roseus and subsequent condensation of the catharanthine and vindoline precursors10. As vincristine and vinblastine were listed as being drugs with a shortage in 2019–2020 by the US Food and Drug Administration11, there is a growing awareness of the importance of refactoring the biosynthesis of MIAs in genetically tractable heterologous hosts. Refactoring complex plant biosynthetic pathways of human therapeutics in microbial hosts could promise more access to plant natural products and new-to-nature derivatives thereof through scalable fermentation12. Indeed, baker’s yeast Saccharomyces cerevisiae has been engineered to produce plant-derived opiates, cannabinoids, terpenes and alkaloids to treat cancer, pain, malaria and Parkinson’s disease12–16. Whereas small parts of the vinblastine biosynthetic pathway have been refactored into yeast4,17–19, only recently was the full 31-step vinblastine biosynthetic pathway from C. roseus explained20,21, opening up the possibility for a demonstration of a microbial supply chain for vinblastine using engineered yeast. BIOSYNTHESIS OF VINBLASTINE The 31-step vinblastine pathway is complex, including dual inlet precursor supplies from tryptophan and geranyl pyrophosphate (GPP) as well as divergence between catharanthine and vindoline supplies towards vinblastine biosynthesis20,21 (Fig. 1). In C. roseus, the enzymes are localized in at least five compartments, namely the cytoplasm, plastid (geraniol synthase)22, endoplasmic reticulum (cytochrome P450s and their reductase), nucleus (strictosidine-O-β-d-glucosidase, SGD)23 and vacuole (strictosidine synthase, STR)23, thus involving trafficking between different tissues and cell types24. To refactor the vinblastine pathway in yeast, we divided the C. roseus pathway into three modules on the basis of substrate/product availability: a strictosidine module including G8H, 8HGO, iridoid synthase, iridoid oxidase, alcohol dehydrogenase 2, 7DLGT, 7DLH, loganic acid O-methyltransferase, secologanin synthase (SLS) and STR4; a tabersonine/catharanthine module including STR (to enable strictosidine production from secologanin and tryptamine feeding), SGD, geissoschizine synthase, geissoschizine oxidase, Redox1, Redox2, SAT, O-acetylstemmadenine oxidase precondylocarpine acetate synthase (PAS), DPAS (dihydroprecondylocarpine acetate synthase), catharanthine synthase and tabersonine synthase20 and a vinblastine module including T16H1, T16H2, 16OMT, T3O, T3R, NMT, D4H, deacetylvindoline-O-acetyltransferase17 and PRX1 (ref. 25) (Fig. 1 and Supplementary Table 1). Furthermore, each module included the expression of C. roseus cytochrome P450 reductase (CroCPR) as well as cytochrome b5 (CroCYB5) to support the cytochrome P450 enzymes. [Figure: Complete biosynthetic pathway for the production of vinblastine in yeast.Yeast genes (orange) overexpressed, dynamically knocked down or deleted are indicated by green arrows, red arrows and red crosses, respectively. Abbreviations not already defined in the text are as follows: IPP, isopentenyl pyrophosphate; DMAPP, dimethylallyl pyrophosphate; GPPS, GPP synthase; FPSN144W, FPP synthase N144W variant; CPR, NADPH-cytochrome P450 reductase; CYB5, cytochrome b5; GES, geraniol synthase; G8H, geraniol 8-hydroxylase; 8HGO, 8-hydroxygeraniol oxidoreductase; ISY, iridoid synthase; IO, iridoid oxidase; CYPADH, alcohol dehydrogenase 2; 7DLGT, 7-deoxyloganetic acid glucosyl transferase; 7DLH, 7-deoxyloganic acid hydroxylase; LAMT, loganic acid O-methyltransferase; TDC, tryptophan decarboxylase; GS, geissoschizine synthase; GO, geissoschizine oxidase; Redox1, protein redox 1; Redox2, protein redox 2; SAT, stemmadenine-O-acetyltransferase; CS, catharanthine synthase; TS, tabersonine synthase; T16H, tabersonine 16-hydroxylase; 16OMT, tabersonine 16-O-methyltransferase; T3O, tabersonine 3-oxygenase; T3R, 16-methoxy-2,3-dihydro-3-hydroxytabersonine synthase; NMT, 3-hydroxy- 16-methoxy-2,3-dihydrotabersonine-N-methyltransferase; D4H, deacetoxyvindoline 4-hydroxylase; DAT, deacetylvindoline-O-acetyltransferase; PRX1, class III peroxidase. The coloured boxes with dashed lines indicate strictosidine (blue), tabersonine/catharanthine (yellow) and vindoline (red) modules. The overlaps between modules are marked as green (overlap between the strictosidine and tabersonine/catharanthine modules) and orange (overlap between the tabersonine/catharanthine and vindoline modules). The information for all genes is also listed in Supplementary Table 1.] A DE NOVO STRICTOSIDINE PLATFORM IN YEAST The initial strictosidine strain MIA-AU was designed on the basis of a previously reported 12-step de novo strictosidine strain, including deletion of ATF1 and OYE2, encoding an alcohol acetyltransferase and a reduced nicotinamide adenine dinucleotide phosphate (NADPH) oxidoreductase, respectively, to minimize by-product formation from geraniol4 (Fig. 1). In addition, MIA-AU was designed to down-regulate ERG20 encoding farnesyl pyrophosphate (FPP) synthase to improve the GPP:FPP ratio. However, when tested in the synthetic complete (SC) medium with all amino acids and 2% glucose, MIA-AU did not produce detectable amounts of strictosidine. Yet, when supplementing 500 μM geraniol to the medium (no higher concentration was tested owing to high toxicity of geraniol above 500 μM, Extended Data Fig. 1), MIA-AU produced 5.59 μg l−1 (10.5 nM) strictosidine, indicating geraniol precursor supply limitations (Fig. 2a). We then deleted the NADPH-dependent aldehyde reductase ARI1 and NADPH oxidoreductase OYE3, involved in syphoning 8-hydroxygeraniol and 8-oxogeranial, respectively, to shunt products26, resulting in strain MIA-AW-2 (Supplementary Table 2). When grown in SC medium supplemented with 500 μM geraniol, MIA-AW-2 produced 12.2 μg l−1 (23.1 nM) strictosidine (Fig. 2a). [Figure: Impact of geraniol on cell growth.A. Growth rates of the wild-type and atf1Δ oye2Δ double knockout